Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Sees Positive Results of PIII Study for Anti-HIV Drug
April 5, 2012
- Ajinomoto Pharmaceuticals Obtains Rights to Develop, Commercialize CC Treatment in Japan, Asia
April 5, 2012
- Ajinomoto Pharmaceuticals Ties Up with DKSH Group in Vietnam
April 5, 2012
- Novartis Draws Up Guidelines for MRs on How to Cope in Times of Disaster
April 4, 2012
- Sogo Rinsho HD to Establish New Subsidiary for Full-Scale Market Entry of CRO Business
April 4, 2012
- Genzyme Changes Distributor of 3 Products Including Thymoglobulin to sanofi-aventis
April 4, 2012
- Abbott Receives Approval for Diagnostic Agent for Identification of Patients for Xalkori Administration
April 4, 2012
- Mochida Aims for Sales of Over 100 Billion Yen in FY2014: New Midterm Management Plan
April 4, 2012
- Top Leaders Stress Importance of Globalization in Addresses to Incoming New Graduates
April 4, 2012
- ALK Inhibitor Xalkori Approved, to Be Provided before NHI Listing: Pfizer Japan
April 3, 2012
- Eisai Licenses Bexarotene Rights to Minophagen in Emerging Countries
April 3, 2012
- Kowa Sets Up Kowa Generic for Generic Business
April 3, 2012
- Kyowa Kirin Applies for Novel Parkinson’s Disease Treatment KW-6002
April 3, 2012
- Shionogi Acquires Global Rights for OncoTheraphy’s Cancer Vaccines
April 2, 2012
- Kyowa Kirin’s Expected Mainstay POTELIGEO Approved
April 2, 2012
- GSK, DSP Begin Copromotion of Paxil CR Tablets from April
April 2, 2012
- Toray, Taiho Terminate Co-Development of β3-Adrenoceptor Agonist
April 2, 2012
- NanoCarrier Enters into Joint Research Agreement with Eisai for Its Drug Discovery Platform Technology
April 2, 2012
- Astellas Enters into Partnership with US Company to Develop, Market Fidaxomicin in Japan
April 2, 2012
- Novartis Files for Add’l Indication of DME for Lucentis
April 2, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…